Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Fas ligand and immune evasion

Nature Medicine volume 2, pages 1306–1307 (1996)Cite this article

Expression of a death factor by tumor cells may explain their escape from immune attack (pages 1361–1366).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Strand, S. et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells-A mechanism of immune evasion? Nature Med. 2, 1361–1366 (1996).

    Article  CAS  Google Scholar 

  2. Hahne, M. et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape. Science 274, 1363–1366 (1996).

    Article  CAS  Google Scholar 

  3. O'Connell, J., O'Sullivan, G.C., Collins, J.K. & Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075–1082 (1996).

    Article  CAS  Google Scholar 

  4. Nagata, S. & Golstein, P. Fas death factor. Science 267, 1449–1456 (1995).

    Article  CAS  Google Scholar 

  5. Alnemri, E. et al Human ICE/CED-3 protease nomenclature. Cell 87, 171 (1996).

    Article  CAS  Google Scholar 

  6. Nagata, S. & Suda, T. Fas and Fas ligand: Ipr and gld mutations. Immunol. Today 16, 39–43 (1995).

    Article  CAS  Google Scholar 

  7. Bellgrau, D. et al. A role for CD95 ligand in preventing graft rejection. Nature 377, 630–632 (1995).

    Article  CAS  Google Scholar 

  8. Griffith, T., Brunner, T., Fletcher, S., Green, D. & Ferguson, T. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189–1192 (1995).

    Article  CAS  Google Scholar 

  9. Lau, H., Yu, M., Fontana, A. & Stoeckert, C., Jr. Prevention of islet lograft rejection with engineered myoblasts expressing FasL in mice. Science 273, 109–112 (1996).

    Article  CAS  Google Scholar 

  10. Tanaka, M. et al. Fas ligand in human serum. Nature Med. 2, 317–322 (1996).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Genetics, Osaka University Medical School, 2-2 Yamada-oka, Suita, Osaka, Japan

    Shigekazu Nagata

Authors
  1. Shigekazu Nagata
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagata, S. Fas ligand and immune evasion. Nat Med 2, 1306–1307 (1996). https://doi.org/10.1038/nm1296-1306

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm1296-1306

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing